Zolpidem safety


Zolpidem efficacy and safety in disorders of consciousness

11.22.2018 by Trinity Alsopp
Zolpidem safety

Brain Inj. 2018;32(4):530-531. doi: 10.1080/ .2018.1429664. Epub 2018 Feb 2. Zolpidem efficacy and safety in disorders of consciousness. Machado.

Generate a file for use with external citation management software.

Sutton and Clauss presented a detailed review about the effectiveness of zolpidem, discussing recoveries from brain damage due to strokes, trauma and hypoxia. A significant finding has been the unexpected and paradoxical increment of brain activity in vegetative state/unresponsive wakefulness syndrome (VS/UWS). On the contrary, zolpidem is considered one of the best sleep inducers in normal subjects. We have studied series of VS/UWS cases after zolpidem intake. As this autonomic imbalance might induce cardio- circulatory complications, which we didn't find in any of our patients, we suggest developing future trials under control of physiological indices by bedside monitoring. However, considering that the paradoxical arousing zolpidem effect might be certainly related to brain function improvement, we agree with Sutton and Clauss that future multicentre and multinational clinical trials should be developed, but under control of physiological indices. We have demonstrated EEG activation, increment of BOLD signal in different brain regions, and an autonomic influence, mainly characterized by a vagolytic chronotropic effect without a significant increment of the vasomotor sympathetic tone.

Zolpidem; autonomic nervous system; heart rate variability; vegetative state/unresponsive wakefulness syndrome.

National Center for Biotechnology Information, U.S. National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA.

Warning: The NCBI web site requires JavaScript to function. more.

The safety and tolerability of zolpidem--an update

10.21.2018 by Morgan Kendal
Zolpidem safety

J Psychopharmacol. 1999;13(1):81-93. The safety and tolerability of zolpidem--an update. Darcourt G(1), Pringuey D, Sallière D, Lavoisy J. Author information:.

Clinically, zolpidem is indicated for the short term treatment of insomnia. The pharmacokinetic profile associated with the absence of active metabolites is consistent with the short duration of action and absence of residual effects that have been observed. Aspects of the general safety of zolpidem have been studied in data obtained from healthy volunteers and patients, both adult and elderly, during its clinical development and in post-marketing experience. Zolpidem appears to be well-tolerated in adults and in the elderly, when administered in accordance with prescribing instructions. Zolpidem belongs to a new class of hypnotic agents, chemically distinct from the pre-existing ones, and has a unique neuropharmacological profile. Polysomnographic experience indicates that zolpidem induces a sleep pattern which is similar to that of physiological sleep, and which produces either no or only minimal effects on sleep architecture after abrupt discontinuation. The available data indicate that, in these circumstances, the risk of abuse or dependence is minimal. It induces sedative/hypnotic effects in rodents at doses much lower than those for anticonvulsant and myorelaxant activities. It has a short half-life (2.4h), with no active metabolite, and does not accumulate during repeated administration.

Generate a file for use with external citation management software.

National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA. National Center for Biotechnology Information, U.S.

Warning: The NCBI web site requires JavaScript to function. more.

Effect and safety of paroxetine combined with zolpidem in treatment

8.19.2018 by Ashley Jeff
Zolpidem safety

Sleep Breath. 2017 Mar;21(1):191-195. doi: 10.1007/s . Epub 2017 Jan 18. Effect and safety of paroxetine combined with zolpidem in.

Generate a file for use with external citation management software.

Eight weeks of the zolpidem combined with paroxetine treatment to patients with primary insomnia is more effective than zolpidem treatment only in sleep maintenance and early morning awakenings.

Compared with the control group, the combined treatment group was more significantly improved on wake time after sleep onset (WASO), total sleep time (TST), sleep efficiency (SE), and total PSQI scores, but not the sleep onset latency (SOL).

Ninety patients meeting DSM-IV criteria for primary insomnia were randomly assigned to 8 weeks of treatment with zolpidem combined with paroxetine (the combined treatment group, n = 45) or zolpidem combined with placebo (the control group, n = 45). Patients were assessed with the Pittsburgh Sleep Quality Index (PSQI), polysomnography (PSG), and the Treatment Emergent Symptom Scale (TESS).

PSQI; Polysomnography; Primary insomnia; Zolpidem combined with paroxetine.

The aim of this study was to determine whether the zolpidem combined with paroxetine would be effective in the treatment of patients with primary insomnia. Primary insomnia is a persistent and recurrent disorder as well as a risk factor for depression.

National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA. National Center for Biotechnology Information, U.S.

Warning: The NCBI web site requires JavaScript to function. more.

Efficacy and safety of modified release zolpidem in patients with

6.17.2018 by Ashley Jeff
Zolpidem safety

Rev Med Inst Mex Seguro Soc. 2012 Sep-Oct;50(5):529-36. [Efficacy and safety of modified release zolpidem in patients with chronic insomnia]. [Article in.

to assess the efficacy and safety of zolpidem modified release (MR) on an "as per needed basis" in patients with chronic insomnia.

one hundred and fifteen patients completed the study; 83.7 % were considered improved or very improved, so that 66 % reached a normal or borderline condition. Twenty percent of subjects experienced adverse reactions; the most frequent were headache, excessive sleepiness, nausea and dizziness.

Warning: The NCBI web site requires JavaScript to function. more.

Generate a file for use with external citation management software.

these data support the efficacy, safety and acceptance of zolpidem MR administered on an "as per needed" regimen for the treatment of chronic insomnia.

National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA. National Center for Biotechnology Information, U.S.

Severity and improvement of insomnia were assessed at baseline and at the end of study using the clinical global impression scale; sleep quality was assessed by the application of the Pittsburgh Sleep Quality Index; drug consumption behavior was evaluated through tablet counting; in addition its security was assessed by the registry of the adverse effects. Participants received zolpidem MR 12.5 mg during a 12 weeks period. one hundred and thirty five adult patients with chronic insomnia were recruited.

Aguilar-Gómez MA, Barragán-Reynaga N, Cuello-Martínez MÁ, de la Garza-Velázquez EA, Fernández-Vera JA, Galván-Jiménez G, Jiménez-Genchi A, López-Ruiz M, Martínez-Esparza J, Pujol-Luna G, Salazar-González JD, Vázquez-Urbieta AG, Veja-García J.

The safety and tolerability of zolpidem an update

5.16.2018 by Emma Anderson
Zolpidem safety

Aspects of the general safety of zolpidem have been studied in data obtained from healthy volunteers and patients, both adult and elderly, during its clinical.

I am signed in via:

With society access I can:

I am signed in via:

Need Help? Contact SAGE.

You can be signed in via any or all of the methods shown below at the same time.

I am signed in as:

Access to society journal content varies across our titles.

With institutional access I can:

Some society journals require you to create a personal profile, then activate your society account.

With my free profile I can:

If you have access to journal content via a university, library or employer, sign in here.

I don't have a profile.

If you have access to a journal via a society or association membership, please browse to your society journal, select an article to view, and follow the instructions in this box.

If you have access to journal via a society or associations, read the instructions below.

You can be signed in via any or all of the methods shown below at the same time.

On your first visit to SAGE Journals please set a new password.

Contact us if you experience any difficulty logging in.